Ikonisys S.A. (EPA:ALIKO)

Market Cap	22.18M +4.1%
Revenue (ttm)	1.64M +62.2%
Net Income	-4.20M
EPS	n/a
Shares Out	15.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,685
Open	1.360
Previous Close	1.400
Day's Range	1.360 - 1.400
52-Week Range	1.340 - 1.840
Beta	0.69
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2026

About Ikonisys

Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that allows scanning and analysis of cells from a voided urine sample; oncoFI...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2021
• Employees: 15
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALIKO

Financial Performance

In 2025, Ikonisys's revenue was 1.64 million, an increase of 62.23% compared to the previous year's 1.01 million. Losses were -4.20 million, 29.7% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error